Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1993 Jul;31(7):1924–1926. doi: 10.1128/jcm.31.7.1924-1926.1993

Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests.

M A Pfaller 1, A L Barry 1, P C Fuchs 1
PMCID: PMC265662  PMID: 8349777

Abstract

Levofloxacin disk susceptibility test criteria were evaluated by testing 350 bacterial isolates. Either 5- or 10-micrograms disks could be used satisfactorily. A 5-micrograms levofloxacin disk with zone size breakpoints of < or = 12 mm for resistance (MIC, > or = 8.0 micrograms/ml) and > or = 16 mm for susceptibility (MIC, < or = 2.0 micrograms/ml) is recommended.

Full text

PDF
1924

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Jones R. N. Temafloxacin disk potency and tentative interpretive criteria for susceptibility tests. J Clin Microbiol. 1989 Dec;27(12):2861–2863. doi: 10.1128/jcm.27.12.2861-2863.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cherubin C. E., Eng R. H., Smith S. M., Tan E. N. A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens. Diagn Microbiol Infect Dis. 1992 Feb;15(2):141–144. doi: 10.1016/0732-8893(92)90038-u. [DOI] [PubMed] [Google Scholar]
  3. Foleno B., Fu K. P. In vitro activity of l-ofloxacin against norfloxacin-resistant coagulase-negative staphylococci. Diagn Microbiol Infect Dis. 1992 Aug;15(6):557–559. doi: 10.1016/0732-8893(92)90109-7. [DOI] [PubMed] [Google Scholar]
  4. Fu K. P., Lafredo S. C., Foleno B., Isaacson D. M., Barrett J. F., Tobia A. J., Rosenthale M. E. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860–866. doi: 10.1128/aac.36.4.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fuchs P. C., Barry A. L., Jones R. N., Thornsberry C. Proposed disk diffusion susceptibility criteria for ofloxacin. J Clin Microbiol. 1985 Aug;22(2):310–311. doi: 10.1128/jcm.22.2.310-311.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fuchs P. C., Jones R. N., Barry A. L., Gavan T. L. Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria. J Clin Microbiol. 1989 Jan;27(1):49–52. doi: 10.1128/jcm.27.1.49-52.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lode H., Höffken G., Olschewski P., Sievers B., Kirch A., Borner K., Koeppe P. Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother. 1987 Sep;31(9):1338–1342. doi: 10.1128/aac.31.9.1338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Metzler C. M., DeHaan R. M. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974 Dec;130(6):588–594. doi: 10.1093/infdis/130.6.588. [DOI] [PubMed] [Google Scholar]
  9. Neu H. C., Chin N. X. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother. 1989 Jul;33(7):1105–1107. doi: 10.1128/aac.33.7.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Okazaki O., Kojima C., Hakusui H., Nakashima M. Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother. 1991 Oct;35(10):2106–2109. doi: 10.1128/aac.35.10.2106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Une T., Fujimoto T., Sato K., Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother. 1988 Sep;32(9):1336–1340. doi: 10.1128/aac.32.9.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES